Integra LifeSciences Holdings Goes Negative
May 6th 2013 1:09AM
Updated May 6th 2013 1:15AM
Integra LifeSciences Holdings (NAS: IART) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged. Non-GAAP earnings per share contracted significantly. GAAP earnings per share shrank to a loss.
Margins contracted across the board.
Integra LifeSciences Holdings recorded revenue of $196.7 million. The 10 analysts polled by S&P Capital IQ expected revenue of $195.2 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.39. The 10 earnings estimates compiled by S&P Capital IQ forecast $0.37 per share. Non-GAAP EPS of $0.39 for Q1 were 45% lower than the prior-year quarter's $0.71 per share. GAAP EPS were -$0.15 for Q1 against $0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 59.2%, 510 basis points worse than the prior-year quarter. Operating margin was 0.0%, much worse than the prior-year quarter. Net margin was -2.1%, 550 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $208.3 million. On the bottom line, the average EPS estimate is $0.52.
Next year's average estimate for revenue is $845.9 million. The average EPS estimate is $2.46.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 153 members out of 163 rating the stock outperform, and 10 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 49 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $44.77.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.
The article Integra LifeSciences Holdings Goes Negative originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.